Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.

In the original publication of this article [1], labelling within Fig. 7a was incorrect. The updated figure is shown below, with 'DMT1' now corrected to read 'DNMT1'.

Correction to: J Exp Clin Cancer Res (2019) 38:474

https://doi.org/10.1186/s13046-019-1442-2

In the original publication of this article [1], labelling within Fig. 7a was incorrect. The updated figure is shown below, with ‘DMT1’ now corrected to read ‘DNMT1’.

Fig. 7

IL-6 increases the expression of OCT4 through DNMT3b and IGF-1R activation in human HCC. a Model of how IL-6 increases theexpression of OCT4 through p-STAT3-DNMT3b-OCT4-DNMT1 activation in human HCC. b The combination use of nanaomycin and sorafenibsynergistically suppresses the cell proliferation of sorafenib resistant HCC cells

The authors sincerely apologize for the inconvenience caused to the readers.